Singh S, et al. - In rheumatoid arthritis (RA), researchers assessed the consequences of tumor necrosis factor-α inhibitors (TNFi), non-TNFi biologic, and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) on cardiovascular risk in this meta-analysis. They noted the association of tocilizumab with a reduced risk of major adverse cardiovascular events (MACE) vs TNFi, csDMARDs were associated with a higher risk of MACE. They also observed that csDMARDs were correlated with increased risk of stroke vs TNFi with no variation in the risk of stroke between different biologics.